文献速递胸部肿瘤

靶向VEGFR的多激酶RET抑制剂RXDX-105的I/Ib期临床试验

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.
PubMed 文献 · Cancer Discov · 2018-11-28

这项I/Ib期试验探索了多激酶RET抑制剂RXDX-105在RET融合阳性肿瘤中的安全性与抗肿瘤活性,确定II期推荐剂量为每日275 mg随餐服用。在未接受过RET抑制剂的RET融合阳性非小细胞肺癌患者中,客观缓解率为19%(95% CI,8%-38%,n=6/31),且缓解率随融合伴侣基因显著不同。

要点

  • II期推荐剂量为RXDX-105每日275 mg随餐服用。
  • RET融合阳性非小细胞肺癌总体客观缓解率为19%(95% CI,8%-38%,n=6/31)。
  • KIF5B融合者客观缓解率为0%(95% CI,0%-17%,n=0/20),非KIF5B融合者为67%(95% CI,30%-93%,n=6/9)。

核心结论

  • 尽管KIF5B-RET是非小细胞肺癌中最常见的RET融合,RXDX-105的RET抑制仅在非KIF5B-RET肿瘤中产生缓解。
  • 需要新的靶向KIF5B-RET肿瘤的方法,并更深入理解导致观察到的差异缓解的生物学机制。

研究设计与样本

  • I/Ib期试验探索多激酶RET抑制剂RXDX-105的安全性和抗肿瘤活性,确定II期推荐剂量为每日275 mg随餐服用。
  • Ib期队列纳入未接受过RET抑制剂的RET融合阳性非小细胞肺癌患者。

主要发现

  • 最常见的治疗相关不良事件为疲乏(25%)、腹泻(24%)、低磷血症(18%)、斑丘疹(18%)和非斑丘疹(17%)。
  • 未接受过RET抑制剂的RET融合阳性非小细胞肺癌患者客观缓解率为19%(95% CI,8%-38%,n=6/31)。
  • 客观缓解率随融合伴侣基因显著不同(P < 0.001,Fisher精确检验):KIF5B融合者为0%(95% CI,0%-17%,n=0/20),非KIF5B融合者为67%(95% CI,30%-93%,n=6/9)。
  • 所有RET融合阳性非小细胞肺癌的中位缓解持续时间未达到(范围,5至18+个月)。

关键数值与推荐

  • II期推荐剂量为RXDX-105每日275 mg随餐服用。
  • 未接受过RET抑制剂的RET融合阳性非小细胞肺癌患者客观缓解率为19%(95% CI,8%-38%,n=6/31)。
  • KIF5B融合者客观缓解率为0%(95% CI,0%-17%,n=0/20),非KIF5B融合者为67%(95% CI,30%-93%,n=6/9),差异P < 0.001(Fisher精确检验)。
  • 所有RET融合阳性非小细胞肺癌的中位缓解持续时间未达到(范围,5至18+个月)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RET fusions are oncogenic drivers of various tumors, including non-small cell lung cancers (NSCLC). The safety and antitumor activity of the multikinase RET inhibitor RXDX-105 were explored in a phase I/Ib trial. A recommended phase II dose of 275 mg fed daily was identified. The most common treatment-related adverse events were fatigue (25%), diarrhea (24%), hypophosphatemia (18%), maculopapular rash (18%), and nonmaculopapular rash (17%). In the phase Ib cohort of RET inhibitor-naïve patients with RET fusion-positive NSCLCs, the objective response rate (ORR) was 19% (95% CI, 8%-38%, n = 6/31). Interestingly, the ORR varied significantly by the gene fusion partner (P < 0.001, Fisher exact test): 0% (95% CI, 0%-17%, n = 0/20) with KIF5B (the most common upstream partner for RET fusion-positive NSCLC), and 67% (95% CI, 30%-93%, n = 6/9) with non-KIF5B partners. The median duration of response in all RET fusion-positive NSCLCs was not reached (range, 5 to 18+ months). SIGNIFICANCE: Although KIF5B-RET is the most common RET fusion in NSCLCs, RET inhibition with RXDX-105 resulted in responses only in non-KIF5B-RET-containing cancers. Novel approaches to targeting KIF5B-RET-containing tumors are needed, along with a deeper understanding of the biology that underlies the differential responses observed.This article is highlighted in the In This Issue feature, p. 305.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Drilon A, Fu S, Patel MR, et al. A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. Cancer Discov. 2018. PMID: 30487236. doi:10.1158/2159-8290.CD-18-0839

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。